{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-065611","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.020282+00:00","generated_at":"2026-05-22T07:20:14.966021+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"aTyr Pharma reports Q1 cash of $78.8M; Phase 3 sarcoidosis data on track for Q3 2025","bullets":["Cash, restricted cash and investments at $78.8M as of March 31, 2025; cash runway sufficient for one year after Phase 3 readout.","Phase 3 EFZO-FIT top-line data (efzofitimod in pulmonary sarcoidosis) expected in Q3 2025; 268 patients enrolled at 85 sites.","Phase 2 EFZO-CONNECT (SSc-ILD) interim data on skin assessments expected in Q2 2025; up to 25 patients.","Appointed Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise; 25+ years industry experience.","R&D expenses $11.8M and G&A $4.0M in Q1 2025; preclinical ATYR2810 data presented at AACR."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-065611","json":"https://secwatch.observer/filing/0000950170-25-065611.json","markdown":"https://secwatch.observer/filing/0000950170-25-065611.md","text":"https://secwatch.observer/filing/0000950170-25-065611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017025065611/0000950170-25-065611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017025065611/atyr-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:20:14.966021+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}